Saltica
Generic Name
Salmeterol Xinafoate
Manufacturer
Acme Pharmaceuticals
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| saltica 25 mcg inhaler | ৳ 595.00 | N/A |
Description
Overview of the medicine
Saltica 25 mcg Inhaler contains Salmeterol Xinafoate, a long-acting beta2-adrenergic agonist (LABA). It is used for the long-term maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD). It helps to open up the airways in the lungs, making breathing easier.
Uses & Indications
Dosage
Adults
For asthma and COPD: 2 inhalations (25 mcg per inhalation) twice daily, approximately 12 hours apart. For prevention of EIB: 2 inhalations (25 mcg per inhalation) at least 30 minutes before exercise.
Elderly
No dosage adjustment is generally required for elderly patients. However, caution is advised due to potential for increased sensitivity.
Renal_impairment
No dosage adjustment is required for patients with renal impairment.
How to Take
For oral inhalation only. Shake the inhaler well before each use. Exhale fully, then place the mouthpiece in your mouth and inhale slowly and deeply while pressing down on the canister. Hold your breath for about 10 seconds, then exhale slowly. Rinse your mouth with water after use to reduce the risk of oral thrush.
Mechanism of Action
Salmeterol acts locally in the lungs as a selective long-acting beta2-adrenergic agonist. It stimulates beta2-receptors on the bronchial smooth muscle, leading to relaxation of the smooth muscle and bronchodilation. This action helps to widen the airways, improving airflow and relieving symptoms of asthma and COPD.
Pharmacokinetics
Onset
Bronchodilatory effect starts within 10-20 minutes.
Excretion
Approximately 25% of the dose is excreted in urine and 75% in feces over 72 hours following oral administration.
Half life
The terminal elimination half-life is approximately 5.5 to 10 hours.
Absorption
Salmeterol is primarily absorbed from the lungs following oral inhalation, with negligible oral bioavailability due to extensive first-pass metabolism. Peak plasma concentrations are reached within 5 to 10 minutes.
Metabolism
Extensively metabolized by hydroxylation via the cytochrome P450 3A4 (CYP3A4) isoenzyme.
Side Effects
Contraindications
- •Primary treatment of status asthmaticus or other acute episodes of asthma or COPD where intensive measures are required.
- •Hypersensitivity to Salmeterol or any component of the formulation.
- •Not indicated for the relief of acute bronchospasm.
Drug Interactions
Diuretics
May potentiate the ECG changes and hypokalemia associated with beta-agonists, especially at high doses.
Non-selective Beta-blockers
May antagonize the effects of Salmeterol and should generally be avoided.
MAO Inhibitors and Tricyclic Antidepressants
May potentiate the cardiovascular effects of Salmeterol. Use with extreme caution.
CYP3A4 Inhibitors (e.g., Ketoconazole, Ritonavir)
May increase Salmeterol plasma concentrations, leading to increased risk of cardiovascular adverse effects.
Storage
Store below 30°C. Protect from direct sunlight, heat, and freezing. Do not puncture or incinerate the canister, even when empty. Keep out of reach of children.
Overdose
Symptoms of Salmeterol overdose include tremor, headache, palpitations, tachycardia, arrhythmias, hypertension, hypotension, and hypokalemia. Management is primarily supportive. Cardiac monitoring may be required. Beta-blockers should be used with caution, as they may induce bronchospasm.
Pregnancy & Lactation
Pregnancy Category C. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether Salmeterol is excreted in human breast milk. Caution should be exercised when administered to a nursing woman.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 24 to 36 months from the date of manufacture. Refer to the product packaging for the exact expiry date.
Availability
Pharmacies, Hospitals
Approval Status
Approved by DGDA
Patent Status
Off-patent
WHO Essential Medicine
YesAlternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in

